Bioadaptives (BDPT) Accumulated Expenses (2018 - 2026)

Bioadaptives has disclosed Accumulated Expenses across 9 years of filings, most recently posting $231534.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $231534.0, up 28.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $231534.0 (up 28.03% YoY), and the FY2025 annual result was $2216.0, down 98.71% from the prior year.
• Accumulated Expenses came in at $231534.0 for Q1 2026 at Bioadaptives, up from $2216.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $231534.0 in Q1 2026 to a low of $1003.0 in Q1 2022.
• The 5-year median for Accumulated Expenses is $137955.0 (2023), against an average of $107442.6.
• Across the five-year window, Accumulated Expenses soared 14223.16% in 2024 and sank 98.71% in 2025, its largest moves.
• Bioadaptives' Accumulated Expenses stood at $100919.0 in 2022, then soared by 36.7% to $137955.0 in 2023, then gained by 24.32% to $171507.0 in 2024, then tumbled by 98.71% to $2216.0 in 2025, then jumped by 10348.29% to $231534.0 in 2026.
• The last three Accumulated Expenses figures came in at $231534.0 (Q1 2026), $2216.0 (Q4 2025), and $203997.0 (Q3 2025), per Business Quant data.